The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Acute Respiratory Distress Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.
Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years.
-
Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment
-
Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.
-
In October 2024, BioAegis Therapeutics, an innovative biotech company focused on developing therapies for inflammatory diseases, is excited to announce the enrollment of the first patient in its Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).
-
In December 2023, Thermo Fisher Scientific Inc.’s PPD clinical research division, a global leader in scientific solutions, has been chosen by the Biomedical Advanced Research and Development Authority (BARDA) to conduct the inaugural BARDA-backed Phase II platform clinical trial. This trial aims to explore various therapeutic avenues for addressing acute respiratory distress syndrome (ARDS). BARDA operates under the Administration for Strategic Preparedness and Response (ASPR), situated within the U.S. Department of Health and Human Services (HHS).
Acute Respiratory Distress Syndrome Overview
Acute Respiratory Distress Syndrome (ARDS) is a severe condition in which the lungs become inflamed and fill with fluid, leading to difficulty breathing and low oxygen levels in the blood. It can result from various causes, including infections, trauma, pneumonia, or inhalation of harmful substances. Symptoms include shortness of breath, rapid breathing, and low oxygen levels. ARDS is a medical emergency that often requires hospitalization, with treatments including oxygen therapy, mechanical ventilation, and addressing the underlying cause. In severe cases, ARDS can lead to organ failure and may be life-threatening.
Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight
Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:
-
RSBT-001: RS BioTherapeutics
-
AVM0703: AVM Biotechnology
-
CYP 001: Cynata Therapeutics
-
AV 001: Vasomune Therapeutics
-
ALT-100: Aqualung Therapeutics
-
STSA-1002: Staidson (Beijing) Biopharmaceuticals
-
GEn-1124: GEn1E Lifesciences
-
Descartes 30: Cartesian Therapeutics
-
Rhu-pGSN: BioAegis Therapeutics Inc.
-
ExoFlo: Direct Biologics, LLC
-
Reparixin 600mg: Dompé Farmaceutici S.p.A
-
Centhaquine: Pharmazz, Inc.
-
ALT-100 mAb: Aqualung Therapeutics Corp.
-
MRG-001: MedRegen LLC
-
TTI-0102: Thiogenesis Therapeutics, Inc.
-
Dexamethasone: Hospital Universitario Infanta Leonor
-
Isoflurane: Guy’s and St Thomas’ NHS Foundation Trust
-
Pirfenidone/Placebo: Fujian Medical University
-
Trimodulin: Biotest
-
AeroFact: Aerogen Pharma Limited
-
Ibudilast: MediciNova
-
Poractant Alfa: NorthShore University HealthSystem
-
Tozorakimab: AstraZeneca
-
L-citrulline: Asklepion Pharmaceuticals
Acute Respiratory Distress Syndrome Route of Administration
Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule Type
Acute Respiratory Distress Syndrome Molecule Type
Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment
-
Acute Respiratory Distress Syndrome Assessment by Product Type
-
Acute Respiratory Distress Syndrome By Stage and Product Type
-
Acute Respiratory Distress Syndrome Assessment by Route of Administration
-
Acute Respiratory Distress Syndrome By Stage and Route of Administration
-
Acute Respiratory Distress Syndrome Assessment by Molecule Type
-
Acute Respiratory Distress Syndrome by Stage and Molecule Type
DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies
Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:
Key companies developing therapies for Acute Respiratory Distress Syndrome are – Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others.
Acute Respiratory Distress Syndrome Pipeline Analysis:
The Acute Respiratory Distress Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
-
Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies
Acute Respiratory Distress Syndrome Pipeline Market Drivers
-
Rising incidence of Acute Respiratory Distress Syndrome, the rising geriatric population are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.
Acute Respiratory Distress Syndrome Pipeline Market Barriers
-
However, increasing Cost of Treatment Therapeutics, lack of Skilled Professionals and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.
Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others
-
Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others
-
Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
-
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers
Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Acute Respiratory Distress Syndrome Report Introduction
2. Acute Respiratory Distress Syndrome Executive Summary
3. Acute Respiratory Distress Syndrome Overview
4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Acute Respiratory Distress Syndrome Pipeline Therapeutics
6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)
7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)
8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)
9. Acute Respiratory Distress Syndrome Preclinical Stage Products
10. Acute Respiratory Distress Syndrome Therapeutics Assessment
11. Acute Respiratory Distress Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acute Respiratory Distress Syndrome Key Companies
14. Acute Respiratory Distress Syndrome Key Products
15. Acute Respiratory Distress Syndrome Unmet Needs
16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers
17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion
18. Acute Respiratory Distress Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/